Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
raleigh-durham blog main
raleigh-durham top stories
8
×
biotech
boston top stories
indiana blog main
indiana top stories
national top stories
san francisco blog main
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
national
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
eli lilly
fda
teva pharmaceutical
cancer
fremanezumab
merck
migraine research foundation
novartis
alder biopharmaceuticals
alnylam pharmaceuticals
bristol-myers squibb
What
drug
8
×
new
8
×
approval
fda
migraine
won
bio
class
companies
decades
drugs
earlier
medicines
oks
roundup
second
year
acute
addresses
adds
advantages
alliance
amgen
approved
areas
arguments
bar
big
biogen’s
biopharmaceutical
biosciences
bio’s
brii
brings
cancer
candidates
causes
cholesterol
commercialized
competitors
Language
unset
Current search:
new
×
drug
×
" raleigh-durham top stories "
×
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines